As of Aug 28
| +0.12 / +1.30%|
The 4 analysts offering 12-month price forecasts for ADMA Biologics Inc have a median target of 20.00, with a high estimate of 24.00 and a low estimate of 17.50. The median estimate represents a +113.45% increase from the last price of 9.37.
The current consensus among 4 polled investment analysts is to Buy stock in ADMA Biologics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.